Radiotherapy bandage composition and method
By embedding carrier nanoparticles or iron garnet nanoparticles in electrospinning bandages, using neutron-activated radiation to treat skin cancer, the problem of expensive equipment and needing patients to remain immobile in the prior art is solved, and maintaining during treatment is achieved Active skin cancer treatment.
Patent Information
- Application Number
- CN202380024697.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-04
- Filing Date
- 2023-03-04
- Publication Date
- 2024-11-29
AI Technical Summary
Existing skin cancer treatments such as Mohs microphotography and radiation therapy require expensive equipment and expertise, and patients need to remain immobile during treatment and cannot remain active during treatment.
Electrospun bandages are used, and carrier nanoparticles or iron garnet nanoparticles are embedded in the bandage. After neutron activation, radiation is emitted evenly on the surface of the bandage. It is used to treat skin cancer. The bandage can be directly applied on the skin and the patient can maintain it during treatment. Activity.
A treatment regimen is provided that does not require surgical or professional equipment, where patients can remain active during treatment and effectively treat skin cancer with uniform radiation, reducing treatment costs and equipment needs.
Smart Images

Figure BDA0005019945330000031 
Figure HDA0005019945340000011 
Figure HDA0005019945340000021
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 268,896, filed on March 4, 2022, under 35 U.S.C. 119, which is incorporated herein by reference in its entirety. Technical Field
[0003] The present invention relates to radiotherapeutic bandages. More particularly, the present invention relates to radiotherapeutic bandages and the use of electrospun radiotherapeutic bandages to treat skin cancer and skin diseases. Background Art
[0004] About one in five Americans will be diagnosed with skin cancer during their lifetime. The most common form of skin cancer is non-melanoma skin cancer (NMSC), and the incidence of NMSC is expected to increase by up to 50% by 2030. This increase is a result of increased exposure to ultraviolet (UV) light. Most NMSC appear on parts of the body that are highly exposed to the sun, such as the face, back of the neck, and hands.
[0005] The most common treatment for removing localized skin lesions is Mohs micrographic surgery (MMS). MMS removes the lesion layer by layer until all signs of the lesion are removed. Radiation therapy is another method used for treatment. There are two main types of radiation therapy used for NMSC: external beam radiation therapy and brachytherapy. Both of these treatments require expensive and specialized machines and require the patient to remain still during treatment.
[0006] Similar treatments are used for other types of illness, infections, and cancer.
[0007] The present invention provides a solution that does not require surgery or specialized equipment. The present invention also allows the patient to remain active during treatment. Summary of the invention
[0008] The present disclosure is directed to radiotherapeutic bandages, compositions of such radiotherapeutic bandages, and methods of making such radiotherapeutic bandages. The present invention further relates to radiotherapeutic bandages and the use of electrospun radiotherapeutic bandages to treat skin cancer and skin diseases.
[0009] In one aspect of the present disclosure, there is provided herein a bandage having an electrospun sheet having polyacrylonitrile nanofibers embedded with carrier nanoparticles or carrier particles, the carrier nanoparticles or carrier particles comprising an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and combinations thereof. The bandage has a laminate shell encasing the electrospun sheet, and the carrier nanoparticles or carrier particles are distributed on the bandage to emit uniform radiation over the entire surface area of the bandage after neutron activation.
[0010] In another aspect of the present disclosure, there is provided herein a bandage having an electrospun sheet having polyacrylonitrile nanofibers embedded with iron garnet nanoparticles or iron garnet particles, the iron garnet nanoparticles or iron garnet particles comprising an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and combinations thereof. The bandage has a laminate shell encasing the electrospun sheet, and the iron garnet nanoparticles or iron garnet particles are distributed on the bandage to emit uniform radiation over the entire surface area of the bandage after neutron activation.
[0011] In another aspect of the present disclosure, a method is provided herein, comprising: preparing a carrier nanoparticle or carrier particle, the carrier nanoparticle or carrier particle comprising iron garnet and an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and combinations thereof; drying the preparation and annealing; grinding the preparation; stirring and heating dimethylformamide (DMF) and polyacrylonitrile (PAN) and forming a concentration of 1 0% to 20% weight / volume PAN / DMF; mixing the preparation and DMF to form a suspension; sonicating the suspension in an ice bath; adding PAN / DMF to the suspension, mixing PAN / DMF and the suspension to form a mixture; adding the mixture to a bracket of an electrospinning apparatus; electrospinning the mixture onto a paper substrate and forming a sheet; cutting the sheet into pieces; wrapping and sealing the pieces with a polymer laminate; forming a bandage by cutting or punching the laminated pieces.
[0012] These and other objects, features and advantages of the present disclosure will become apparent from the following detailed description of the various aspects of the disclosure taken in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1Table depicting activatable nuclides incorporated into particles or nanoparticles according to one or more embodiments described herein;
[0014] Figure 2 Depicting method steps for forming a neutron activated bandage according to one or more embodiments described herein;
[0015] Figure 3 depicts XRD of HoIG after angular sonication confirming its garnet structure according to one or more embodiments described herein;
[0016] Figure 4A Depicting a sheet of siliconized kraft paper on top of one or more embodiments described herein. 165 Ho electrospun sheets;
[0017] Figure 4B Describes a method according to one or more embodiments described herein. Figure 4A having a substantially uniform distribution of nanofibers 165 Dark-field optical imaging of Ho electrospun sheets;
[0018] Figure 5 Describes a method for implementing a method of ... Figure 4A Bandage sheets cut and laminated from electrospun sheets;
[0019] Figure 6 Describes a method for implementing a method of ... Figure 5 Individual rectangular bandages cut from bandage sheet material;
[0020] Fig. 7A Depicts a circular laminate containing a 165 Ho electrospun bandage;
[0021] Figure 7B Describes a method according to one or more embodiments described herein. Fig. 7A The laminate contains 165 Second view of the Ho electrospun bandage. DETAILED DESCRIPTION
[0022] Generally stated, disclosed herein are devices, systems, and methods for treating skin cancer.
[0023] As used herein, the terms "a", "an" or "the" may refer to one or more than one. For example, "a" tag may mean one tag or a plurality of tags.
[0024] As used herein, the term "about" when used with respect to a measurable value, such as an amount of mass, dose, time, temperature, etc., is intended to encompass variations from the specified amount. Variations may include, for example, as much as ±10% or as little as ±0.1% of the specified amount, including all variations therebetween.
[0025] As used herein, the term "activatable nuclide" refers to a non-radioactive nuclide that can be activated to produce a radionuclide. For example, iron garnet nanoparticles and particles are supports that can be prepared using lanthanide nuclides (e.g., holmium, dysprosium, lanthanum, praseodymium, and / or samarium), rare earth nuclides (e.g., yttrium and / or rhenium nuclides) that become activated by neutron irradiation. Certain embodiments provide iron garnet nanoparticles and particles as supports prepared using one of the following nuclides: yttrium, holmium, dysprosium, lanthanum, praseodymium, samarium, and / or rhenium. The following table provides examples of activatable nuclides and corresponding radionuclides.
[0026] Table 1. Nuclides incorporated into nanoparticles (For a more detailed version of this table, see Figure 1 )
[0027]
[0028] In some other embodiments, the Figure 1 The polymer-based nanoparticles or particles of the carriers of the various activatable nuclides listed in the present invention are used to dope or incorporate the activatable nuclides into the polymer-based nanoparticles or particles. This includes polymerizing and coating or encapsulating the activatable nuclides into a polymer matrix. In some cases, chelators can be used on the radionuclides to be connected to the polymer structure. Examples of polymer-based nanoparticles can include dextran, poly (lactide) (PLA), poly (lactide-co-glycolide) (PLGA) copolymers, poly (ε-caprolactone) (PCL) and poly (amino acids), as well as some natural polymers such as alginate, chitosan, gelatin and albumin.
[0029] In some other embodiments, the Figure 1 The activatable nuclide is doped or incorporated into the carbon-based nanoparticles or particles as a carrier of the various activatable nuclides listed in the present invention. Examples of carbon-based nanomaterials or material carriers include, but are not limited to, mesoporous carbon nanoparticles (MCNs), carbon nanotubes (CNTs) (including single-walled carbon nanotubes (SWNTs), SWNTs coated with a polydopamine (PDA) shell, and SWNTs coated with a polydopamine (PDA) shell modified with polyethylene glycol (PEG)), fullerenes, carbon dots (CDs), nanodiamonds, and graphene and its derivatives, such as graphene oxide nanoparticles (GONs) (including non-covalently PEGylated GONs (GON-PEG)).
[0030] In some other embodiments, the Figure 1 The activatable nuclides are doped or incorporated into the lipid-based nanoparticles or particles by using lipid-based nanoparticles or particles as carriers of the various activatable nuclides listed in .
[0031] In some other embodiments, the Figure 1 The activatable nuclides are doped or incorporated into the silica-based nanoparticles or particles by using silica-based nanoparticles or particles as carriers of the various activatable nuclides listed in. The silica-based nanoparticles may include, for example, mesoporous silica nanoparticles (MSN), zeolites, or silica metal organic framework composites.
[0032] In yet other embodiments, the activatable species may be doped or incorporated into a carrier such as quantum dots, gold nanoparticles, silver nanoparticles, rare earth fluoride nanoparticles, and / or metal oxide nanoparticles, for example.
[0033] As used herein, the term "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items as well as no combinations when interpreted in the alternative ("or").
[0034] As used herein, the terms "increase" and "enhance" (and any grammatical variations of these terms) refer to an increase in a specified parameter of at least about 1% to 300% or more, including any and all parameter values therebetween.
[0035] As used herein, the terms "inhibit" and "reduce" (and any grammatical variations of these terms) refer to a reduction in a specified parameter by at least about 1% to 99% or more, including any and all parameter values therebetween.
[0036] As used herein, the term "nanofiber" (and any grammatical variations thereof) refers to a fiber having a diameter of about 0.1 nm to about 350 nm. The term "fiber" (and any grammatical variations thereof) refers to a polymer fiber having a diameter between about 0.1 nm and 1 μm. In some embodiments, the diameter of the fiber or nanofiber is about 5 nm to about 100 nm or about 5 nm to about 350 nm. In some embodiments, the fibers or nanofibers have a diameter of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 975, or 999 nm.
[0037] As used herein, the term "nanoparticle" (and any grammatical variations thereof) refers to a particle having a diameter of about 0.1 nm to about 250 nm. The term "particle" (and any grammatical variations thereof) refers to an iron garnet particle having a diameter between about 0.1 nm and 1 μm. In some embodiments, the particle or nanoparticle has a diameter of about 5 nm to about 100 nm or about 5 nm to about 250 nm. In some embodiments, the diameter of the particle or nanoparticle is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 975, or 999 nm. The particles and nanoparticles disclosed herein refer to carrier nanoparticles and particles in which a specific activatable nuclide is complexed. Carrier particles and nanoparticles may refer to, for example, polymer-based nanoparticles or particles, carbon-based nanoparticles or particles, lipid-based nanoparticles or particles, silica-based nanoparticles or particles, graphene-based nanoparticles or other nanoparticles in which specific activatable nuclides are compounded. Particles and nanoparticles disclosed herein may refer to, for example, iron garnet nanoparticles or iron garnet particles in which specific activatable nuclides are incorporated. These carrier particles and nanoparticles may include, for example, yttrium, holmium, lanthanum, praseodymium, samarium, rhenium and / or dysprosium dispersed in the carrier particles and nanoparticles. Certain embodiments provide iron garnet nanoparticles or iron garnet particles containing holmium nuclides. Certain embodiments provide iron garnet nanoparticles or iron garnet particles containing activatable nuclides (e.g., yttrium, holmium, dysprosium, lanthanum, praseodymium, samarium and / or rhenium) dispersed in iron garnet nanoparticles or iron garnet particles. Certain embodiments provide carrier nanoparticles and particles, which may refer to, for example, polymer-based nanoparticles or particles, lipid-based nanoparticles, silica-based nanoparticles, or other nanoparticles, which contain activatable nuclides (e.g., yttrium, holmium, dysprosium, lanthanum, praseodymium, samarium and / or rhenium) contained within the carrier particles and nanoparticles.
[0038] As used herein, "pharmaceutically acceptable" means that the material is suitable for administration to an individual and will allow the desired treatment to proceed without undue deleterious side effects. In determining whether any particular side effect is unduly deleterious, the severity of the disease and the necessity of the treatment are generally considered.
[0039] As used herein, the term "radiotherapeutic nanoparticle" refers to a nanoparticle that emits radiation. As used herein, the term "radiotherapeutic particle" refers to a particle or nanoparticle that emits radiation. The term "radionuclide" refers to an atom with an unstable nucleus that undergoes radioactive decay and emits gamma rays and / or other subatomic particles (e.g., beta particles). Figure 1 A list of neutron activatable nuclides for incorporation into particles or nanoparticles is provided in , listing the activatable nuclides and their corresponding radionuclides. Examples of activatable nuclides include: 165 Ho, 164 Dy, 89 Y. 139 La, 152 Sm, 141 Pr, 185 Re and 187 Re. Examples of this type of radionuclide include: 166 Ho, 165 Dy, 90 Y. 140 La, 153 Sm, 142 Pr, 186 Re and 188 Re. In certain embodiments, nanoparticles and / or particles containing activatable nuclides are irradiated / activated under neutron irradiation and produce radioactive therapeutic nanoparticles and / or radioactive therapeutic particles, so that the radioactive therapeutic nanoparticles and / or radioactive therapeutic particles emit therapeutic levels of radiation. In certain embodiments, radioactive therapeutic nanoparticles and / or radioactive therapeutic particles are activated by neutron irradiation so that the nanoparticles or particles emit low "sub-therapeutic" levels of radiation and have little effect on cells around the location of the nanoparticles. Sub-therapeutic levels of radiation can be used, for example, in combination with radiosensitizers.
[0040] As used herein, the term "subject" (and grammatical variations thereof) refers to a mammal, bird, reptile, amphibian, or fish. Mammalian subjects may include, but are not limited to, humans, non-human primates (e.g., monkeys, chimpanzees, baboons, etc.), dogs, cats, mice, hamsters, rats, horses, cattle, pigs, rabbits, guinea pigs, ferrets, sheep, and goats. Avian subjects may include, but are not limited to, chickens, turkeys, ducks, geese, quail, pheasants, and birds kept as pets (e.g., parakeets, parrots, macaws, cockatoos, etc.). In specific embodiments, the subject is an experimental animal. Human subjects may include neonates, infants, adolescents, adults, and elderly subjects. The therapeutic and sub-therapeutic variants of the embodiments of the present invention may, for example, be used for subjects.
[0041] As used herein, the term "therapeutically effective" refers to some improvement or benefit to an individual. Alternatively stated, a "therapeutically effective amount" is an amount that will provide some relief, alleviation or attenuation of at least one clinical symptom of an individual (e.g., for individuals with a form of cancer, a reduction in tumor size, a reduction in the incidence of cancer metastasis, etc.). Those skilled in the art will appreciate that the therapeutic effect does not have to be complete or curative, as long as some therapeutic benefit is provided to the individual. The concentration of the stable activatable particles (or nanoparticles) and / or radiotherapeutic agents in the pharmaceutical composition may vary greatly (i.e., less than about 0.05% to about 90% or more by weight) depending on the specific mode of administration, the disease / disorder / symptom to be treated, the age / weight of the individual, etc. In certain embodiments, the concentration of the stable activatable particles or nanoparticles may be varied.
[0042] As used herein, the terms "treatment", "treat" or "treating" refer to providing the particles and / or nanoparticles disclosed herein to a subject in an effort to alleviate, lessen or attenuate at least one clinical symptom of the subject.
[0043] The methods of the present invention can be used to treat any suitable condition known in the art, including but not limited to bacterial infection, viral infection, cancer, trigeminal neuralgia, severe thyroid eye disease, pterygium, pigmented villonodular synovitis, vascular restenosis, heterotopic ossification, rheumatoid arthritis, synovial osteochondromatosis, synovial chondromatosis and joint bleeding. In some embodiments, the condition is a hematological cancer or cancer. As understood by those skilled in the art, embodiments of the present invention can be used to treat cancer forms. As an example, non-melanoma skin cancer can be treated by embodiments of the present invention. Those skilled in the art will also understand that embodiments of the present invention can be used to treat skin diseases. Examples of such skin diseases include: actinic keratosis, psoriasis, infantile hemangioma, etc.
[0044] The present invention provides radioactive therapeutic nanoparticles and radioactive therapeutic particles. In certain embodiments, the present disclosure provides iron garnet nanoparticles or iron garnet particles containing activatable nuclides, such as holmium and / or Figure 1 Other activatable nuclides shown in the table. Therefore, one aspect of the present invention provides a stable activatable iron garnet nanoparticle or particle, which comprises an activatable nuclide precursor, consists essentially of it, or consists of it. Another aspect of the present invention provides a pharmaceutical composition, which comprises, consists essentially of, or consists of the disclosed iron garnet nanoparticles and / or iron garnet particles and a pharmaceutically acceptable carrier.
[0045] One aspect of the present invention provides an electrospun bandage impregnated with the iron garnet (commonly referred to as IG) nanoparticles or particles disclosed herein. As used herein, the term "bandage" (and any grammatical variations thereof) refers to a wound, trauma or growth covering into which the disclosed IG nanoparticles or particles are impregnated. Such bandages may be formed from an electrospun fabric, an electrospun patch, an electrospun sheet, an electrospun mat or an electrospun membrane. In some embodiments of this aspect of the invention, the bandage is produced by dispersing the disclosed IG nanoparticles or particles and dissolving the polymer in a solvent, applying a stable nuclide solution to a release paper by a coating machine and drying. The bandage may then be irradiated with neutrons in a nuclear reactor. Another embodiment of the disclosed invention provides for the use of electrospinning technology to prepare a bandage loaded with 165 Ho nanofibers, which can be electrospun into bandages with uniform nanoparticle or particle distribution. In certain embodiments, the nanofibers can be loaded with 165 Activatable nuclides other than Ho, such as 164 Dy, 89 Y. 139 La, 152 Sm, 141 Pr, 185 Re and 187 Re. In the above examples, IG can be a carrier of a nuclide (e.g., Ho) and other determined activatable nuclides. In certain embodiments, the size of the nanoparticles or particles used in the manufacture of electrospun fabrics, electrospun patches, electrospun sheets, electrospun mats, or electrospun membranes can be less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, less than about 50 nm. In certain other embodiments, the size of the particles used in the manufacture of electrospun fabrics, electrospun patches, electrospun sheets, electrospun mats, or electrospun membranes can be less than about 400 μm, less than about 200 μm, less than about 100 μm, less than about 50 μm, less than about 20 μm, less than about 10 μm, less than about 5 μm.
[0046] In certain other embodiments, carriers other than IG nanoparticles and particles may be used. Doping or incorporation of activatable nuclides into polymer nanoparticles and particles may be performed to form polymer nanoparticles and particles for use in Figure 1 The carriers of various activatable nuclides listed in . Examples of other carriers include, but are not limited to, mesoporous silica nanoparticles (MSN), mesoporous carbon nanoparticles (MCN), carbon nanotubes (CNT) (including single-walled carbon nanotubes (SWNT), SWNT coated with a polydopamine (PDA) shell, and SWNT coated with a polydopamine (PDA) shell modified with polyethylene glycol (PEG)) and graphene oxide nanoparticles (including non-covalently PEGylated GON (GON-PEG)).
[0047] The polymer dissolved with the nanoparticle or particles placed in the solvent can include, for example: biodegradable polymers, polylactic acid, polycaprolactone, poly(glycolic acid) (PGA), polydioxanone, polyanhydride, polyorthoester, poly(amino acid), chitosan and sulfonated chitosan. Other polymer examples include: water-soluble polymers such as poly(vinyl pyrrolidone)) (PVP), poly(ethylene oxide) (PEG), poly(vinyl alcohol) (PVA) and poly(acrylic acid) (PAA) and mixtures thereof. Still other polymer examples include: nylon, polyester, polyamide, poly(amic acid), polyimide, polyether, polyketone, polyurethane, polycaprolactone, polyacrylonitrile, polyaramid, polybenzimidazole, poly(2-methoxy, 5-ethyl(2'; hexyloxy) p-phenylene) (MEH-PPV), polystyrene, polyvinylarene, polythiophenevinyl, polypyrrolevinyl, polyheteroarylvinyl, polyaniline, polyphenylene, polyarylene, polythiophene, polypyrrole, polyheteroarylene, polyphenylene vinylene, polyarylene, polythiophene vinylene, polyheteroarylene, polyphenylene vinylene, polyarylene vinylene, polythiophene vinylene, polyheteroarylene vinylene, and mixtures thereof. Other polymers may be used, but it is preferred that the polymer remain stable to at least the nuclide activation temperature.
[0048] As used herein, the phrases "relatively uniform distribution of the nanoparticles / particles within the electrospun fabric, electrospun patch, electrospun sheet, electrospun mat, or electrospun membrane" and "relatively uniform radiation over the entire surface area of the electrospun fabric, electrospun patch, electrospun sheet, electrospun mat, or electrospun membrane" relate to the distribution of nanoparticles / particles and the radiation emitted by the nanoparticles / particles within the electrospun fabric, electrospun patch, electrospun sheet, electrospun mat, or electrospun membrane. In this regard, the change in the number of nanoparticles / particles or the amount of radiation emitted from a given surface area of an electrospun fabric, electrospun patch, electrospun sheet, electrospun mat, or electrospun membrane varies by less than about 30%, less than about 25%, less than about 15%, less than about 10%, less than about 5%, or less than about 1%. Although the terms electrospun fabric, electrospun patch, electrospun sheet, electrospun mat, and / or electrospun membrane have been used, these terms may be used interchangeably.
[0049] Example for preparing radiotherapy bandages .
[0050] Preparation of nanostructured ... 165 The input materials and preparation for electrospinning are described below. 12or commonly referred to as HoIG) was produced using the methods described in: Munaweera I, Levesque-Bishop D, Shi Y, Di Pasqua AJ, Balkus Jr KJ., Radiotherapeutic bandage based on electrospun polyacrylonitrile containing holmium-166 iron garnet nanoparticles for the treatment of skin cancer. ACS Appl Mater Interfaces; and Koneru B, Shi Y, Munaweera I, Wight-Carter M, Kadara H, Yuan H, Di Pasqua J, et al., Radiotherapeutic bandage based on electrospun polyacrylonitrile containing holmium-166 iron garnet nanoparticles for the treatment of skin cancer. ACS Appl Mater Interfaces; Pasqua AJ, Balkus Jr KJ., Radiotherapeutic bandage for the treatment of squamous cell carcinoma of the skin. Nucl Med Biol. HoIG was dried and annealed at 950°C for 4 hours. It was gently ground using a mortar and pestle to break down agglomerates. Dimethylformamide (anhydrous, 99.8%) (DMF) and polyacrylonitrile (MW 150,000) (PAN) were used as received from MilliporeSigma. 14.29% w / v PAN / DMF (referred to herein as "concentrated PAN / DMF") was produced by heating and stirring overnight. 1.21 g of holmium iron garnet was poured into 3.43 g of DMF in a glass vial and vortex mixed at 3000 rpm for 2 minutes. The holmium / DMF suspension was sonicated in an ice bath using a 3 mm diameter probe on a VCX 130 angle sonicator (Sonics and Materials Inc.) at a power density of 104.6 kWs / mL. After sonication, 8.30 g of concentrated PAN / DMF was added to the suspension and the mixture was vortexed at 3000 rpm for 5 minutes.The final mixture was immediately poured into the 10 mL carriage of a NS Lab roll-to-roll electrospinning instrument and spin coated onto a 50 cm wide siliconized kraft paper substrate under the following conditions: substrate speed: 5 mm / min; carriage speed: approximately 180 cm / s; electrode distance: 180 mm; voltage: 80 kV; humidity: approximately 18% to 21%; temperature: approximately 20° C. to 35° C. The mat formed can be, for example, a nonwoven. The electrospun mat was clamped at 212° F. (100° C.) for 20 seconds and cut into 0.5" diameter circles with an Orion Motor Tech 40W CO2 laser cutter using the following conditions: 6% laser power and 20 mm / s vector cut.
[0051] The electrospun mat may be distributed with nanofibers and fibers having a range of diameters and distributed with nanoparticles and particles having a range of diameters. For example, the majority diameter of the nanofibers or fibers in the nonwoven fabric forming the mat may be from about 100 nm to about 350 nm. For example, the majority diameter of the nanoparticles or particles may be from about 15 nm to about 250 nm. However, smaller sizes provide better packaging of the nuclides in the carrier and better packaging in the mat. The thickness of the electrospun mat in turn affects the emission efficiency, with thinner mats having higher emission efficiency.
[0052] X-ray powder diffraction (XRD) was used to characterize 165 Ho iron garnet (HoIG) nanoparticles, dark field optical imaging was used to determine the size uniformity of the nanofibers in the electrospun mats, and inductively coupled plasma mass spectrometry (ICP-MS) was used to measure the Ho and iron (Fe) content of the mats and the uniformity of the mats. Six different areas were cut on three different A4 mats and the values were obtained.
[0053] The sheets were laser cut and laminated with approximately 25.4 μm (0.001") thick wear-resistant nylon (McMaster-Carr, Princeton, NJ) and cut again to ensure complete encapsulation of the holmium-containing nanofibers or fibers, nanoparticles or particles. The tensile strength of the wear-resistant nylon used was approximately 11,200 psi to 12,300 psi (77220 kPa to 84805 kPa). The hot press was preheated to 425 °F (218 °C) (GeoKnight Jet Press 14). A siliconized release paper backing and a single wear-resistant nylon sheet (McMaster-Carr Product 8539K199) were placed on the base of a heat press, and 0.5" (12.7 mm) round PAN-HoIG composite pieces were placed in an array on the nylon sheet, with the edge-to-edge spacing between sample pieces being approximately 0.75 in (about 19 mm). A second wear-resistant nylon sheet was placed on the opposite side of the piece, thereby completely encapsulating the piece in the laminate. The first and second nylon sheets sealed the piece. A final siliconized release paper layer was placed on the piece array. The spacing between the pieces provided a boundary surrounding the piece and provided a lamination area that could be used to cut or punch a bandage while maintaining a complete seal of the electrospun PAN-HOIG composite piece.
[0054] The layers placed in the heat press unit were set up as release paper-nylon sheet-HoIG block sheet-nylon sheet-release paper. The heat press was operated at 425°F (about 218°C) for approximately 30 seconds and the material was allowed to cool in air. The heat press was operated for approximately 30 more seconds.
[0055] The laminated array of pieces was cooled to room temperature and wiped with Kimwipes. Next, the pieces were punched out using a 0.75in (about 19mm) die punch and hammer. The electrospun fiber sample was completely encapsulated in the laminate, thereby maintaining the nanofibers and fibers and nanoparticles and particles therein. In an alternative embodiment, the sample can be cut into smaller pieces of desired size and / or shape.
[0056] The laminated samples were at 7.5 × 10 12 Neutrons / cm 2 Neutron activation (or neutron irradiation) was performed at 10 s for 10 h, and radioactivity was quantified in the NC state. A certified mixed nuclide standard was used for calibration to analyze 1379 keV 166 High purity germanium detector for the Ho peak and associated Canberra MCA gamma spectrometry system. 166 The Ho 1379 keV peak has a lower gamma yield than the 81 keV peak, but the uncertainty in measuring the detector efficiency at that energy is much less than at 81 keV.
[0057] In the described works, wear resistant nylon was used. In certain embodiments of the process, other polymer laminates may be used, such as polyester, polypropylene or polyethylene. The laminate may include a film or sheet. The laminate heating time may vary with the thickness of the laminate and the type of material.
[0058] In certain embodiments of the process, laminate samples formed in a clean room environment can eliminate the need to use Kimwipes or similar clean tools. Although the use of Kimwipes is mentioned, other clean tools can also be used.
[0059] In some embodiments, the thickness of the nylon laminate can be thinner or thicker than 25.4 μm. Nylons with a thickness of less than 25.4 μm can be used. In an activated bandage, the thinner the nylon laminate film, the higher the permeability of the film to beta particles. Although thicker nylon laminate films can be used, beta emissions can be hindered by the thicker laminate material. At bandage thicknesses suitable for placement on the skin surface, gamma emissions are not significantly hindered. However, beta particle emission has been determined to be therapeutically effective for diseases such as skin cancer, and it is desirable to maximize the permeability of the film to beta particles.
[0060] The measurements used in the examples describe a specific embodiment. However, one skilled in the art will appreciate that the measurements and materials can be adjusted to form input materials for the electrospinning process to form a desired output. Furthermore, the measurements and materials can be adjusted to form input materials for electrospinning devices of different types and sizes under different operating conditions and parameters.
[0061] In another example, the drying and annealing temperature of the HoIG may be in a range of about 800° C. to about 1250° C. In yet another example, the drying and annealing time length may be in a range of about 2 hours to about 10 hours.
[0062] Standard commercially available dimethylformamide (anhydrous, 99.8%) (DMF) and polyacrylonitrile (MW 150,000) (PAN) were used. Other concentrations and molecular weights may be used. For example, DMF with a lower water content is preferred, but higher water concentrations may also be used. Additionally, PAN with lower or higher molecular weights may be used.
[0063] In the example, the PAN / DMF concentration is described as 14.29%. However, in other examples, the concentration of PAN / DMF can be, for example, approximately 10% to approximately 20%. PAN / DMF can be used.
[0064] In an example, 1.21 g of HoIG is poured into 3.43 g of DMF and mixed to form a suspension. In certain other embodiments, these amounts may be adjusted depending on the electrospinning device used, the output size of the mat, and the desired concentration of HoIG. The amount of HoIG may be approximately 1 g to 2 g and the amount of DMF may be approximately 2.8 g to 5.7 g. Ultrasonic treatment of the suspension may be performed to inhibit particle or nanoparticle agglomeration and maximize dispersion to form a substantially uniform suspension. The ultrasonic treatment time and power density used to form a substantially uniform suspension may vary depending on the ultrasonic treatment device used. Although ultrasonic treatment is a preferred method for forming a substantially uniform suspension, other standard laboratory devices may also be used. Continuing with the example, 8.3 g of PAN / DMF is added to the HoIG / DMF mixture. In other examples, the added PAN / DMF may be approximately 6.8 g to 13.7 g.
[0065] Although the above process of making a bandage is described using holmium-165, other activatable nuclides may be used, such as yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and / or any combination thereof, and / or in combination with holmium- 165. A carrier such as iron garnet may be combined with the activatable nuclides to produce a bandage.
[0066] refer to Figure 2 , forming a PAN electrospun mat with HoIG nanoparticles 100. At this point the mat can be cut into pieces, such as strips or circles or squares. The term cutting is used to form smaller pieces of the desired size and / or shape, but these pieces can also be punched into the desired size and / or shape. The HoIG nanoparticles are distributed in a stable nuclide state within the electrospun bandage 110. Although strips or circles or squares are mentioned, the bandage can be cut into pieces of any shape. The cut pieces are laminated and completely sealed. The pieces of the electrospun bandage are placed in a reactor where non-radioactive 165 Ho is made radioactive by neutron activation 166 Ho 120. After neutron activation, 166 Ho emits beta particles and gamma photons when it decays.An adhesive may also be applied to the activated cut pieces, for example, to form a bandage 130 that is attached to the patient's skin.The cut pieces of the activated bandage may be applied to the skin area 140 that requires treatment.
[0067] In another embodiment, mesoporous silica may be used instead of pyrope as a carrier of the nuclide.
[0068] Figure 3 The XRD of HoIG after angular ultrasonic treatment is shown and its garnet structure is confirmed.
[0069] Figure 4AA4 size sheet displayed on siliconized kraft paper top 165 Ho Pan pad. Figure 4B Showing uniform distribution of nanofibers 165 Dark-field optical imaging of the Ho pad.
[0070] refer to Figure 5 ,according to Figure 4A and 4B The electrospun sheet can be cut into pieces 401 and a laminate 403 is applied to wrap the pieces, thereby forming a laminated piece 400. Figure 5 , rectangular pieces 401 of electrospun material are of generally uniform size and are positioned with sealed laminate boundaries between adjacent pieces. Figure 6 , a bandage 410 is formed after one of the laminated sheets 401 and a sealed laminate border 405 is cut from the sheet of laminated sheet 400. The bandage 410 is completely wrapped in the laminate material so that the top and bottom surfaces are covered in the laminate material and the sealed border covers the sides of the electrospun sheet.
[0071] picture Fig. 7A and 7B Shows the content before neutron activation 165 An embodiment of a Ho electrospun laminate bandage 500. Bandage 500 shows a circular electrospun sheet 501 wrapped in a laminate material 503, wherein the laminate material 503 has a larger diameter than the electrospun sheet and provides a sealed boundary. Although bandage 500 is shown as circular, bandage 500 can have any shape, including, for example, square, rectangular, oval, or any other type of adhesive bandage shape.
[0072] Figures 6 to 7A The bandage depicted in can be disposed of more safely after activation because the electrospun fibers and electrospun nanofibers are enclosed within the laminate.
[0073] refer to Fig. 7A and 7B , when the weight is approximately 23mg, 500 at 7.5×10 12 Neutrons / cm 2 When neutron activation was performed at 400 μg / mL for 10 h and the radioactivity was analyzed on five separate occasions in the NC state, the average radioactivity immediately after the 10 h activation was 9.9±2.2 mCi (n=5).
[0074] refer to Figure 2 The process described refers to a HoIG bandage. However, those skilled in the art will appreciate that a similar process is applicable to a bandage having a Figure 1Bandages are made from pads of iron garnet nanoparticles and particles of the activatable nuclides listed in. In other embodiments, carriers other than iron garnet may be used, including: polymer-based nanoparticles or particles, lipid-based nanoparticles or particles, silica-based nanoparticles or particles, and other carriers. Carriers other than iron garnet may contain, for example, Figure 1 Activatable nuclides listed in .
[0075] In other embodiments, the laminated samples are approximately 7.5×10 12 Neutrons / cm 2 Neutron activation is performed at a thermal neutron flux of 10 s for more than 10 h. Lower and higher thermal neutron fluxes (including up to 10 13 Neutrons / cm2·s). Neutron activation times may include, for example, approximately 1 h, 2 h, 4 h, 5 h, 10 h, 15 h, 20 h, 24 h, 48 h, 72 h, and longer. These neutron activation times are applicable to iron garnet nanoparticles and iron garnet particles having activatable holmium nuclides. These neutron activation times may also be applicable to iron garnet nanoparticles and iron garnet particles having one or more of the activatable nuclides (e.g., holmium, dysprosium, lanthanum, praseodymium, samarium, and / or rhenium) contained within the iron garnet particles or iron garnet nanoparticles. The benefit of a longer activation time is that since activation is proportional to radioactivity, there is flexibility in providing a decay period to achieve the desired radioactivity.
[0076] The activation time can be applied, for example, to carriers other than iron garnet, including: polymer-based nanoparticles or particles, lipid-based nanoparticles or particles, silica-based nanoparticles or particles, and other carriers. Such carriers can be incorporated with, for example, Figure 1 Activatable nuclides listed in .
[0077] In other embodiments, the thickness of the nylon laminate may vary depending on the activatable nuclide used. For activatable nuclides with beta emission, a thinner nylon laminate film encapsulating the bandage provides higher beta emission penetration. A thicker nylon laminate film is suitable when it does not hinder beta particle therapy.
[0078] In other embodiments, cut pieces of electrospun polymer nanofibers or fiber patches, fabrics, sheets or mats may be laminated, whether prepared by needle electrospinning or needleless electrospinning. By fully laminating the pieces, the polyacrylonitrile nanofibers or PAN fibers are contained within the laminated shell and prevented from interacting with the skin or diseased or tumor surface. By fully laminating the pieces, the carrier nanoparticles and particles infused with the nuclide are contained within the laminated shell and prevented from interacting with the skin or diseased or tumor surface even when the nuclide is activated.
[0079] In some embodiments, the bandage may be treated with a material that acts as a "radiosensitizer." Radiosensitizer compounds are drugs that act in combination with radiation to produce an improved response, typically making DNA more sensitive to radiation or extending the life of free radicals generated by radiation. Such radiosensitizers may be applied, for example, to the outside of a laminated sealing bandage or directly to the skin exhibiting a skin disease or tumor site. For cancer therapy, the goal is to selectively enhance the effect of the dose on the tumor.
[0080] Described below is a method of making a bandage formed of carrier particles or nanoparticles with one or more radiotherapeutic nanoparticles.HoIG is produced by drying a HoIG preparation, annealing the HoIG preparation, and grinding the holmium garnet to break down agglomerates to form a powder.
[0081] The next step forms the input material for electrospinning. A mixture of dimethylformamide (anhydrous, 99.8%) (DMF) and polyacrylonitrile (MW 150,000) (PAN) is stirred and heated until a PAN / DMF concentration of 14.29% weight / volume is formed. Powdered HoIG is mixed with DMF to form a suspension. The suspension is placed in an ice bath and sonicated.
[0082] At this point, the PAN / DMF mixture and the holmium iron garnet powder can be moved to a first clean room where electrospinning is performed. It is preferred but not essential to use the material and move it to the first clean room. The PAN / DMF mixture is added to the holmium iron garnet / DMF suspension and mixed to form a mixture, which is then loaded into an electrospinning instrument. The mixture is added to a bracket of an electrospinning instrument (e.g., a needleless roller-to-roller electrospinning instrument). The electrospinning instrument continues to spin-coat the mixture into fibers to form a pad on a paper substrate. The pad can be cut into pieces by, for example, a stamping or laser cutting tool. The pieces can be placed in a container. The container can be moved to a second clean room to assist in minimizing cross contamination of materials that do not contain HoIG and / or nanofibers from the outer surface of the piece during lamination. It is preferred but not essential to use the piece and move it to a second clean room.
[0083] The next step is the lamination process. The pieces can be removed from the container and wrapped in a polymer such as a wear-resistant nylon. Other polymers such as polyester, polypropylene or polyethylene can also be used.
[0084] The outer laminate surface may be cleaned to minimize or remove any HoIG and / or nanofiber material from the surface. The tiles may be packaged for shipping.
[0085] The patch can be removed from the packaging or kept in the packaging for activation. The patch can be irradiated / activated with neutron irradiation so that the radioactive therapeutic nanoparticles emit therapeutic levels of radiation. An adhesive can be added to one side of the patch.
[0086] For treatment, the adhesive side of the patch can be placed on an area of the patient's skin for treatment. The length of treatment and the number of treatments can depend on the nature of the skin disease or cancer.
[0087] The methods described can be used to produce electrospun sheets using carrier nanoparticles or other combinations of carrier particles with the nuclides listed herein. In addition, laminates can be used to completely wrap these variations of electrospun sheets to form encased radiotherapeutic bandages.
[0088] The corresponding structures, materials, actions, and equivalents (if any) of all members or step-plus-function elements in the following claims are intended to include any structure, material, or action for performing a function in combination with other required elements as specifically required. The description of one or more embodiments is presented for the purpose of illustration and description, but is not intended to be exhaustive or limited to the disclosed forms. Many modifications and variations will be apparent to those of ordinary skill in the art. The embodiments are selected and described in order to best illustrate various aspects and practical applications, and to enable other persons of ordinary skill in the art to understand various embodiments with various modifications that are suitable for the intended specific use.
[0089] Although several aspects of the invention have been described and depicted herein, those skilled in the art may implement alternative aspects to accomplish the same objectives. Therefore, the appended claims are intended to cover all such alternative aspects that fall within the true spirit and scope of the invention.
Claims
1. A bandage comprising: An electrospun sheet, comprising: Polyacrylonitrile nanofibers embedded with carrier nanoparticles or carrier particles, the carrier nanoparticles or carrier particles comprising: an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and any combination thereof; and a laminate housing encasing the electrospun sheet; and The carrier nanoparticles or the carrier particles are distributed on the bandage to emit relatively uniform radiation over the entire surface area of the bandage after neutron activation.
2. A bandage according to claim 1, wherein the carrier nanoparticles or the carrier particles further comprise a carbon-based material.
3. The bandage of claim 1, wherein the carrier nanoparticles or the carrier particles further comprise a lipid-based material.
4. The bandage of claim 1, wherein the carrier nanoparticles or the carrier particles further comprise a silica-based material.
5. The bandage of claim 1, wherein the carrier nanoparticles or the carrier particles comprise a polymer-based material.
6. The bandage of claim 1, wherein the carrier nanoparticles or the carrier particles comprise a graphene-based material.
7. The bandage of claim 2, wherein the carbon-based material consists of mesoporous carbon.
8. The bandage of claim 4, wherein the silica-based material consists of mesoporous silica.
9. The bandage of claim 1 wherein the laminate is polymeric and completely encases the bandage.
10. The bandage of claim 9, wherein the polymer is selected from the group consisting of nylon, polyester, polypropylene, polyethylene, and combinations thereof.
11. A bandage according to claim 10, wherein the laminate covers the entire surface of the bandage and provides a sealed border around the sides of the bandage.
12. The bandage of claim 11, wherein one surface of the bandage is coated with an adhesive.
13. The bandage of claim 10 wherein the laminate is nylon and has a tensile strength of at least 77220 kPa.
14. A bandage according to claim 13, wherein the thickness of the laminate is equal to or less than 0.5 mm.
15. The bandage of claim 13, wherein the thickness of the laminate is equal to or less than 25.4 μm.
16. The bandage of claim 1, wherein the polyacrylonitrile nanofibers have a diameter of about 100 nm to about 350 nm.
17. The bandage of claim 16, wherein the polyacrylonitrile nanofibers have a diameter of about 150 nm to about 250 nm.
18. The bandage of claim 1, wherein the nanoparticles or particles have a diameter of about 15 nm to about 250 nm.
19. The bandage of claim 18, wherein the nanoparticles have a diameter of about 15 nm to about 200 nm.
20. A bandage comprising: An electrospun sheet, comprising: Polyacrylonitrile nanofibers embedded with iron garnet nanoparticles or iron garnet particles, the iron garnet nanoparticles or iron garnet particles comprising: an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and any combination thereof; and a laminate housing encasing the electrospun sheet; and The iron garnet nanoparticles or the iron garnet particles are distributed on the bandage to emit relatively uniform radiation over the entire surface area of the bandage after neutron activation.
21. The bandage of claim 20, wherein the laminate shell is a polymer that completely encases the bandage.
22. The bandage of claim 21, wherein the laminate is selected from the group consisting of nylon, polyester, polypropylene, polyethylene, and combinations thereof.
23. A bandage according to claim 22, wherein the laminate covers the entire surface of the bandage and provides a sealed border around the sides of the bandage.
24. A bandage according to claim 23, wherein one surface of the bandage is coated with an adhesive.
25. The bandage of claim 22 wherein the laminate is nylon and has a tensile strength of at least 77220 kPa.
26. A bandage according to claim 22, wherein the thickness of the laminate is equal to or less than 0.5 mm.
27. The bandage of claim 22, wherein the laminate has a thickness equal to or less than 25.4 μm.
28. The bandage of claim 20, wherein the polyacrylonitrile nanofibers or polyacrylonitrile fibers have a diameter of about 100 nm to about 350 nm.
29. The bandage of claim 28, wherein the polyacrylonitrile nanofibers or polyacrylonitrile fibers have a diameter of about 150 nm to about 250 nm.
30. The bandage of claim 20, wherein the nanoparticles or particles have a diameter of about 15 nm to about 250 nm.
31. The bandage of claim 30, wherein the nanoparticles or particles have a diameter of about 15 nm to about 200 nm.
32. The bandage of claim 20, wherein the activatable nuclide is holmium-165.
33. A method of forming a radiotherapeutic bandage, comprising: a. preparing a carrier nanoparticle or carrier particle, the carrier nanoparticle or carrier particle comprising an iron garnet and an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and combinations thereof; b. drying the preparation and annealing; c. grinding the preparation; d. stirring and heating dimethylformamide (DMF) and polyacrylonitrile (PAN) to form a concentration of 10% to 20% weight / volume PAN / DMF; e. mixing the preparation and DMF to form a suspension; f. subjecting the suspension to ultrasonic treatment in an ice bath; g. adding PAN / DMF to the suspension; h. mixing PAN / DMF and the suspension to form a mixture; i. adding the mixture to the bracket of the electrospinning instrument; j. electrospinning the mixture onto a paper substrate to form a sheet; k. Cutting the slice into pieces; l. Wrapping and sealing the piece with a polymer laminate; and m. Forming a bandage by cutting or punching the wrapped and sealed laminated piece.
34. The method of claim 33, wherein steps a. to f. are performed in the first space.
35. The method of claim 34, wherein after step f., the PAN / DMF and the carrier particles / DMF suspension are moved to a first clean room and steps g. to k. are performed.
36. The method of claim 35, wherein after step k., the pieces are placed in a clean container, moved to a second clean room and step l. is performed.
37. The method of claim 35, wherein cleaning is performed after each of steps g. to k.
38. The method of claim 36, wherein cleaning is performed after step 1.
39. The method of claim 33, further comprising activating the bandage using neutron activation.
40. The method of claim 39, further comprising adding an adhesive to one side of the bandage.
41. The method of claim 33, wherein the PAN / DMF concentrate is stirred and heated to produce 14.29% weight / volume PAN / DMF.
42. The method of claim 41, wherein 1.21 g of holmium iron garnet is mixed with 3.43 g of DMF to form a suspension.
43. The method of claim 42, wherein the suspension is sonicated to form a homogenous suspension.
